Advanced therapy medicinal products (ATMPs) are medicines for human use that are based on genes, tissues or cells. They offer groundbreaking opportunities for the treatment of disease and injury. ATMPs differ from more "classic" drugs because they are not based on molecules produced by chemical synthesis but on DNA or RNA, cells and fabrics. ATMPs are an emerging sector of biomedicine, the result of the enormous progress made in the last twenty years in the field of biotechnology, and offer new opportunities for the diagnosis, prevention or treatment of serious pathologies, from genetic and chronic diseases to severe burns or injuries.
This webcast will highlight how ATMP therapies are working together with cell and gene therapies to help combat cancer, indicating that cell and gene therapies can reshape healthcare, giving hope to patients who previously had no therapeutic options. It will also demonstrate how recent solutions for GMP production in closed systems can be easily scalable, sustainable, and flexible, improving patient access while ensuring companies and hospitals maintain a competitive edge.
The webcast will show how lab productivity can be dramatically improved, enabling a complete rethink of lab facilities and showing how a well-trained workforce is crucial in driving the future of ATMPs, including compliance with regulatory authorities. BioAir (recently acquired by Tecniplast) is the leading developer of solutions for GMP production in closed systems. The presenters will propose a synergic participation model, based on co-design and engagement between healthcare, industry, and academia, to aid the identification of solutions to address a variety of health needs.
You will:
• Increase your awareness about ATMPs and their fast evolution
• Increase your knowledge about the use of closed systems for ATMP manufacturing
• Perceive how lab productivity, sustainability and flexibility can be dramatically improved through ATMP isolators
Unable to join the live event? Watch on demand. Register now to ensure that you receive information on how to gain access after the live event.
This webcast has been produced by BioAir, a Tecniplast Company, who retains sole responsibility for content. About this content.
Speakers
Charles Lawrie, Director of Oncology Research Area, Biodonostia Health Research Institute
Charles Lawrie obtained his BA Hons in Biochemistry, MA and DPhil at Trinity College, University of Oxford. Following several postdoctoral positions, he launched the Lymphoid Malignancy Research Group (LMRG) at the Nuffield Department of Clinical Laboratory Sciences (NDCLS), part of the University of Oxford’s Medical Sciences Division. He joined the Biodonostia HRI in 2011 as an Ikerbasque Research Professor, Coordinator of the Oncology Area, and Leader of the Molecular Oncology Research Group. Dr Lawrie has published more than 100 publications, including two books and 9 book chapters, and is the co-inventor of 4 patents.
Ander Izeta, Tissue Engineering Laboratory Head, Hospital Universitario Donostia
Dr Izeta leads the Tissue Engineering Group at Biodonostia Health Research Institute and acts as associate lecturer in Regenerative Medicine at Tecnun-University of Navarra, in San Sebastian, Spain. His research group has contributed to our understanding of human skin regeneration and repair, including human epidermal and dermal stem cells, and is deciphering their implications for human wound healing. He has also been involved in clinical trials, for epidermolysis bullosa and for chronic cutaneous leg ulcers.
Moderator
Sarah Hiddleston, Nature Research Custom Media
Sarah Hiddleston is a freelance journalist who has worked with Nature Research Custom Media since 2015. Previously, Sarah worked for a decade in Madras (Chennai), India, specialising in health, pharmaceutical and environmental stories. Sarah holds an MA in Investigative Journalism from City University London, an MSc in Political Theory from the London School of Economics, and an undergraduate degree in History from the University of Cambridge, UK.
